Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 50

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru · 2021 · Cancer Science

Abstract

Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, and pharmacokinetics of milademetan in 18 Japanese patients with solid tumors who relapsed after or were refractory to standard therapy. Patients aged ≥ 20 years received oral milademetan once daily (60 mg, n = 3; 90 mg, n = 11; or 120 mg, n = 4) on days 1 to 21 in a 28‐day cycle. Dose‐limiting toxicities, safety, tolerability, maximum tolerated dose, pharmacokinetics, and recommended dose for phase II were determined. The most frequent treatment‐emergent adverse events included nausea (72.2%), decreased appetite (61.1%), platelet count decreased (61.1%), white blood cell count decreased (50.0%), fatigue (50.0%), and anemia (50.0%). Dose‐limiting toxicities (three events of platelet count decreased and one nausea) were observed in the 120‐mg cohort. The plasma concentrations of milademetan increased in a dose‐dependent manner. Stable disease was observed in seven out of 16 patients (43.8%). Milademetan was well tolerated and showed modest antitumor activity in Japanese patients with solid tumors. The recommended dose for phase II was considered to be 90 mg in the once‐daily 21/28‐day schedule. Future studies would be needed to further evaluate the potential safety, tolerability, and clinical activity of milademetan in patients with solid tumors and lymphomas. The trial was registered with Clinicaltrials.jp: JapicCTI‐142693.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.14875

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 13

  1. 10.1101/cshperspect.a026104 · DOI · Paper page
  2. 10.1177/1947601911408889 · DOI · Paper page
  3. 10.3389/fphar.2020.00631 · DOI
  4. 10.1126/science.1092472 · DOI · Paper page
  5. NCBI. National Center for Biotechnology Information.PubChem Compound Summary for CID 73297272 Milademetan. Milademetan.https://pubchem.ncbi.nlm.nih.gov/compound/Milademetan. Accessed Jul. 19 2020.2020.
  6. 10.1200/JCO.2018.36.15_suppl.11514 · DOI
  7. 10.1002/sim.3230 · DOI · Paper page
  8. 10.1016/j.ejca.2008.10.026 · DOI · Paper page
  9. 10.1038/nrd4288 · DOI
  10. 10.1186/s13045-017-0500-5 · DOI · Paper page
  11. 10.1007/s00280-015-2830-8 · DOI
  12. 10.1038/s41416-018-0355-8 · DOI · Paper page
  13. 10.1182/bloodadvances.2019030916 · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., Sakajiri, S., & Yamamoto, N.
Affiliations
  • The Cancer Institute Hospital of JFCR Tokyo Japan
  • Department of Respiratory Medicine Mitsui Memorial Hospital Tokyo Japan
  • Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan
  • Quantitative Clinical Pharmacology Pharmacokinetics Department Daiichi Sankyo Co., Ltd Tokyo Japan
  • Data Intelligence Department Daiichi Sankyo Co., Ltd Tokyo Japan
  • Oncology Medical Science Department Daiichi Sankyo Co., Ltd Tokyo Japan
  • Juntendo Urayasu Hospital Urayasu Japan
Venue
Cancer Science
Publisher
Wiley
Published
2021-05-02
Volume
112
Issue
6
Pages
2361-2370
ISSN
  • 1347-9032
  • 1349-7006
Cited by
50
References
9
Language
en
Funders
Daiichi Sankyo Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. https://app.cochat.ai/papers/10.1111/cas.14875
The paper
Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., Sakajiri, S., & Yamamoto, N. (2021). Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer Science. https://doi.org/10.1111/cas.14875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.